Ingevity - NGVT Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NGVT shares.
View NGVT analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1-year price targets for Ingevity's shares. Their NGVT share price forecasts range from $76.00 to $87.00. On average, they expect the company's stock price to reach $81.50 in the next year. This suggests that the stock has a possible downside of 1.1%.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $70.44 at the beginning of 2023. Since then, NGVT stock has increased by 17.0% and is now trading at $82.39.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) released its earnings results on Wednesday, October, 27th. The company reported $1.62 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.08. The company had revenue of $376.80 million for the quarter, compared to analysts' expectations of $354.29 million. Ingevity had a trailing twelve-month return on equity of 36.37% and a net margin of 13.90%. Ingevity's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.79 EPS.

Ingevity updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.65 billion-$1.70 billion, compared to the consensus revenue estimate of $1.60 billion.

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.96%), New York State Common Retirement Fund (0.46%), Allspring Global Investments Holdings LLC (0.23%), Gateway Investment Advisers LLC (0.10%), Natixis Advisors L.P. (0.09%) and Peterson Wealth Services (0.07%). Insiders that own company stock include D Michael Wilson, Diane H Gulyas, Erik Spencer Ripple, Frederick J Lynch, John C Fortson, Michael P Smith, Richard Allen White Jr, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends.

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NGVT stock can currently be purchased for approximately $82.39.

Ingevity (NYSE:NGVT) has a market capitalization of $3.08 billion and generates $1.39 billion in revenue each year. The company earns $118.10 million in net income (profit) each year or $5.81 on an earnings per share basis.

The company employs 1,850 workers across the globe.

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for the company is www.ingevity.com. The company can be reached via phone at (843) 740-2300, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.